Journal of Clinical Hepatology
This article studies the real-world efficacy and safety of coloprevir combined with sofosbuvir ± ribavirin in the treatment of chronic hepatitis C. The study included 253 patients, including two groups: compensated liver cirrhosis (CLC) and chronic hepatitis C (CHC), and followed up and evaluated the SVR12 (sustained virological response 12 weeks after treatment) rate and adverse reactions after 12 weeks of treatment. The results showed that the overall SVR12 reached 92.09%, with 93.02% in the CLC group and 91.02% in the CHC group, with no significant difference, indicating that the scheme has high efficacy in patients with different conditions. Multivariate analysis showed that age and a history of hepatocellular carcinoma (HCC) were independent factors affecting SVR. In terms of safety, the incidence of adverse events was 23.72%, mainly fatigue and nausea, with only 1.58% serious adverse reactions, indicating good tolerance. The innovation lies in providing large sample data support for the domestic innovative drug coloprevir in the real clinical environment, filling the evidence gap in its real-world application, and is particularly valuable for reference for the distribution characteristics of HCV genotypes in the southwest region of China (mainly type 3).
This study explores the efficacy and safety of coloprevir combined with sofosbuvir ± ribavirin in the treatment of chronic hepatitis C virus (HCV) infection, which has important clinical significance. The study included 253 patients, and the results showed that the overall SVR12 (virus clearance rate 12 weeks after treatment) reached 92.09%, with 93.02% in the CLC group and 91.02% in the CHC group, indicating that the scheme has high antiviral efficacy in patients with different conditions. Multivariate analysis showed that age and a history of HCC were independent factors affecting SVR12, suggesting the need to strengthen monitoring of high-risk populations. In addition, the ALT, AST, TBil, and liver stiffness (LSM) of patients after treatment were significantly improved, indicating that liver function and fibrosis were significantly alleviated. In terms of safety, adverse reactions were mainly fatigue (17.39%) and nausea (2.37%), most of which were mild and could be self-resolved, with only 1.58% serious adverse events, and no patients discontinued treatment due to this, indicating good tolerance of the scheme. The research results support the effectiveness and safety of the combined scheme in the real world, providing data support for individualized clinical treatment.
Objective: To investigate the therapeutic efficacy, influencing factors, and safety of a treatment regimen based on coblopasvir hydro…
